AgaMatrix Enters Strategic Partnership with Arcadia Group for Choice Brand Diabetes Monitoring Devices
AgaMatrix and Arcadia Group announced today a strategic partnership leveraging AgaMatrix’s proprietary blood glucose monitoring (BGM) technology for the Choice line of diabetes products marketed by Arcadia.
With a robust portfolio of branded and private label products for diabetes care, AgaMatrix is pleased to partner with Arcadia to offer consumers more options in accessing accurate, affordable BGM technology. AgaMatrix’s core technology, WaveSense, enables world-class accuracy by utilizing dynamic electrochemistry to detect and correct for common sources of interference. AgaMatrix’s innovative technology and manufacturing expertise has established them as a preferred manufacturer of diabetes devices for top retailers and pharmaceutical partners.
Arcadia Group has designed a traditional and wireless BGM offering under the Choice brand, which will be sold exclusively through a leading e-commerce giant. The Choice blood glucose monitor will offer wireless transfer of blood glucose data to the AgaMatrix Diabetes Manager App, delivering a simplified data management experience across AgaMatrix’s mobile and HIPAA-compliant cloud platform. The AgaMatrix Diabetes Manager App is compatible with Apple and Android devices, and also works with Apple Health for consolidated viewing of health and activity data.
“The opportunity with Arcadia to bring our accurate BGM technology and connected health platform to a unique player in the ecommerce market at a competitive cost and feature profile is very promising,” said John Alberico, CEO of AgaMatrix. “This combination is sorely needed in a healthcare market increasingly filled with rising deductibles and unaffordable therapies. We are proud to offer people with diabetes a way to safely test in an affordable, convenient manner.”
Bob Guest, CEO of Arcadia Group, commented “The Choice brand is all about accessible wellness. Partnering with Amazon means consumers no longer need to drive to a store to stand in line and purchase their medical devices and supplies. Now, in the privacy of their home, consumers can review, compare and purchase products of their choice. No prescriptions or insurance is required; therefore, customers have the freedom of choice. Gone are the days when insurance companies dictate what product you have to purchase. Choice is freedom.”
The Arcadia Group draws from extensive experience launching diabetes care products, including the development of successful brands such as ReliOn® and FreeStyle. Choice will be the first e-commerce centric offering from Arcadia. Arcadia also plans to offer a range of Choice branded products for monitoring hypertension, and other potential line extensions for the diabetes and cardiovascular markets.
For more information about Choice products view the Arcadia Group press release https://www.choiceplus.health/press-release
About AgaMatrix Holdings LLC
AgaMatrix, Inc. is a developer of diagnostic technologies for glucose monitoring and wholly owned subsidiary of AgaMatrix Holdings LLC. Based in New Hampshire, AgaMatrix develops, manufactures, and markets innovative solutions for blood glucose monitoring and data management on mobile and cloud platforms. AgaMatrix has sold over 8 million blood glucose monitors and over 3 billion test strips since the Company’s 2001 inception.
WaveForm Technologies, a wholly owned subsidiary of AgaMatrix Holdings LLC, develops innovative technology for continuous glucose monitoring based on a unique, needle-free sensor design. Multiple clinical trials have been completed for their continuous glucose monitoring technology and accompanying software, and will be concluding shortly to support a regulatory filing and clearance in the European Union.